Palvella Therapeutics, Inc.
PVLA
$50.13
-$3.29-6.16%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 8.82% | 108.28% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 17.52% | 80.28% | |||
| Operating Income | -17.52% | -80.28% | |||
| Income Before Tax | -15.71% | -107.16% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -15.71% | -107.16% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -15.71% | -107.16% | |||
| EBIT | -17.52% | -80.28% | |||
| EBITDA | -- | -- | |||
| EPS Basic | -15.30% | -142.96% | |||
| Normalized Basic EPS | -15.31% | -45.66% | |||
| EPS Diluted | -15.30% | -142.96% | |||
| Normalized Diluted EPS | -15.31% | -45.66% | |||
| Average Basic Shares Outstanding | 0.35% | 0.01% | |||
| Average Diluted Shares Outstanding | 0.35% | 0.01% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||